Barclays analyst Peter Lawson has reiterated their neutral stance on BMEA stock, giving a Hold rating yesterday. Peter Lawson has given his ...

Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's ongoing ...

Fintel reports that on September 26, 2024, Rodman & Renshaw upgraded their outlook for Biomea Fusion (NasdaqGS:BMEA) from ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...

Biomea Fusion said the Food and Drug Administration lifted its clinical hold on continuing clinical trials of the company's diabetes drug.

The drug, BMF-219, is being tested in an early-to-mid stage study for type 2 diabetes and a mid-stage study for type 1 ...

Biomea Fusion said on Thursday the U.S. Food and Drug Administration lifted a clinical hold on ongoing studies of its ...

NDAQ:BMEA) Biomea Fusion, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Shareholder Participation In An Inquiry ...

NDAQ:BMEA) Investors Are Invited To Help The Schall Law Firm Investigate Whether Biomea Fusion Inc Committed Securities Fraud ...

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of the lymph nodes. The development of novel targeted therapies and ...